Glucidion G 5

Glucidion G 5 is an intravenous solution containing glucose anhydrous, potassium chloride, and sodium chloride. It is supplied in a sterile liquid form intended for infusion. The product is manufactured for the European market and is used as an electrolyte and carbohydrate source in clinical settings. No specific strength or dosage form is listed, and it is administered under medical supervision by qualified healthcare professionals.

Glucidion G 5 may be employed in medical practice for several supportive purposes related to fluid and electrolyte management.

- Providing an immediate source of glucose for patients unable to intake carbohydrates orally. - Replenishing potassium and sodium levels during or after surgical procedures. - Assisting in the correction of mild electrolyte imbalances in hospitalized patients. - Supporting hydration and energy needs in patients receiving parenteral nutrition. - Facilitating the management of hypoglycemia when rapid intravenous glucose is required.

Intravenous administration of Glucidion G 5 can be associated with a range of observed effects, which are generally categorized by frequency and severity.

Common: - Mild nausea or vomiting - Transient headache - Local irritation at the infusion site

Serious: - Severe hyperglycemia - Significant hyperkalemia with cardiac risk - Fluid overload leading to pulmonary edema

When using Glucidion G 5, healthcare providers should observe several precautionary measures to minimize risks and ensure appropriate patient monitoring.

- Assess baseline blood glucose, potassium, and sodium levels before infusion. - Adjust infusion rate in patients with renal impairment or heart failure. - Monitor cardiac rhythm continuously if high potassium concentrations are administered. - Avoid rapid infusion in patients at risk for fluid overload. - Use caution in individuals with known hypersensitivity to any component of the solution. - Re‑evaluate electrolyte status regularly during prolonged therapy.

Glucidion G 5 may interact with other medications or solutions; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent administration of other potassium‑rich intravenous solutions without adjusting total potassium dose. - Co‑infusion with high‑glucose formulations that could precipitate severe hyperglycemia. - Use with medications that prolong the QT interval when significant electrolyte shifts are expected.

Use with caution: - Diuretics that affect potassium balance, requiring close electrolyte monitoring. - Insulin therapy, as combined effects may alter glucose levels rapidly. - Calcium channel blockers, especially in the setting of hyperkalemia.